Shionogi Pharmaceutical Co., Ltd., a pharmaceutical company headquartered in Osaka, uses a domestic vaccine under development as the third "booster vaccination" for people who have been vaccinated twice for the new coronavirus vaccine for half a year. It was revealed that the test was started.
According to the announcement, "Shionogi Pharmaceutical" is a domestic vaccine currently under development as the third to third inoculation for people who have been inoculated twice for half a year after inoculating the new coronavirus "messenger RNA vaccine" twice. I started a clinical trial using.
In the study, 100 people who received the Pfizer vaccine for the third time and 100 people who received the Shionogi vaccine will be compared to evaluate the safety and efficacy.
While there are concerns about the prolonged spread of the vaccine worldwide, such as the infection of the new mutant virus "Omicron strain" being confirmed all over the world, the company will continue to need a stable supply of vaccines, and it is domestically produced. We hope to realize the development of the vaccine within this year.
Shionogi said, "The third vaccination has started this month, and overseas vaccines are being secured, but domestic vaccines are needed to achieve a stable supply in Japan."